Cwm LLC Purchases 190 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Cwm LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,565 shares of the pharmaceutical company’s stock after buying an additional 190 shares during the quarter. Cwm LLC’s holdings in Vertex Pharmaceuticals were worth $2,264,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. abrdn plc raised its stake in shares of Vertex Pharmaceuticals by 196.0% in the fourth quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock worth $236,410,000 after acquiring an additional 384,730 shares during the last quarter. BSN CAPITAL PARTNERS Ltd bought a new position in Vertex Pharmaceuticals in the 4th quarter valued at $81,378,000. Northern Trust Corp increased its stake in shares of Vertex Pharmaceuticals by 4.9% in the 3rd quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock valued at $978,388,000 after buying an additional 131,539 shares during the period. International Assets Investment Management LLC boosted its holdings in Vertex Pharmaceuticals by 21,750.1% in the fourth quarter. International Assets Investment Management LLC now owns 115,150 shares of the pharmaceutical company’s stock valued at $46,853,000 after acquiring an additional 114,623 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in Vertex Pharmaceuticals by 110.1% in the third quarter. Panagora Asset Management Inc. now owns 201,519 shares of the pharmaceutical company’s stock worth $70,076,000 after purchasing an additional 105,608 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on VRTX shares. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 20th. Royal Bank of Canada upped their price target on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 6th. Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and increased their price target for the company from $332.00 to $379.00 in a research report on Wednesday, January 24th. Oppenheimer reissued an “outperform” rating and set a $500.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Finally, Truist Financial upped their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $429.45.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 2,656 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the transaction, the chairman now directly owns 27,644 shares in the company, valued at $11,596,934.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,381 shares of company stock worth $5,203,249. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.8 %

NASDAQ:VRTX opened at $397.70 on Friday. The firm has a market capitalization of $102.79 billion, a price-to-earnings ratio of 28.63, a price-to-earnings-growth ratio of 1.89 and a beta of 0.35. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a twelve month low of $316.43 and a twelve month high of $448.40. The stock’s 50 day moving average price is $412.09 and its two-hundred day moving average price is $398.37.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the company posted $3.33 earnings per share. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.